HealthCare Global Enterprises Gelecekteki Büyüme

Future kriter kontrolleri 4/6

HealthCare Global Enterprises kazanç ve gelirin sırasıyla yıllık 59.7% ve 14.5% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 57.5% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 14.9% olacağı tahmin edilmektedir.

Anahtar bilgiler

59.7%

Kazanç büyüme oranı

57.5%

EPS büyüme oranı

Healthcare kazanç büyümesi	28.0%
Gelir büyüme oranı	14.5%
Gelecekteki özkaynak getirisi	14.9%
Analist kapsamı	Good
Son güncelleme	07 Mar 2025

Gelecekteki son büyüme güncellemeleri

HealthCare Global Enterprises Limited Just Missed Earnings - But Analysts Have Updated Their Models

Nov 13

HealthCare Global Enterprises Limited Just Missed EPS By 79%: Here's What Analysts Think Will Happen Next

Feb 11

Recent updates

Pinning Down HealthCare Global Enterprises Limited's (NSE:HCG) P/S Is Difficult Right Now

Dec 22

HealthCare Global Enterprises Limited Just Missed Earnings - But Analysts Have Updated Their Models

Nov 13

We Take A Look At Why HealthCare Global Enterprises Limited's (NSE:HCG) CEO Compensation Is Well Earned

Sep 19

HealthCare Global Enterprises Limited Just Missed EPS By 79%: Here's What Analysts Think Will Happen Next

Feb 11

We Think Shareholders Will Probably Be Generous With HealthCare Global Enterprises Limited's (NSE:HCG) CEO Compensation

Sep 14

A Look At The Fair Value Of HealthCare Global Enterprises Limited (NSE:HCG)

Sep 05

HealthCare Global Enterprises Limited's (NSE:HCG) Business Is Yet to Catch Up With Its Share Price

May 17

Does HealthCare Global Enterprises (NSE:HCG) Have A Healthy Balance Sheet?

Jun 24

Shareholders Shouldn’t Be Too Comfortable With HealthCare Global Enterprises' (NSE:HCG) Strong Earnings

Jun 03

Is HealthCare Global Enterprises (NSE:HCG) Using Too Much Debt?

Dec 08

Kazanç ve Gelir Büyüme Tahminleri

NSEI:HCG - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (INR Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
3/31/2027	29,426	1,835	2,788	N/A	6
3/31/2026	26,202	1,030	1,477	N/A	6
3/31/2025	22,478	450	-865	N/A	5
12/31/2024	21,323	583	N/A	N/A	N/A
9/30/2024	20,436	570	923	3,468	N/A
6/30/2024	19,770	526	N/A	N/A	N/A
3/31/2024	19,121	482	989	2,846	N/A
12/31/2023	18,592	353	N/A	N/A	N/A
9/30/2023	18,140	371	922	2,197	N/A
6/30/2023	17,471	309	N/A	N/A	N/A
3/31/2023	16,944	293	1,184	2,516	N/A
12/31/2022	16,174	270	N/A	N/A	N/A
9/30/2022	15,507	-264	1,156	2,364	N/A
6/30/2022	14,827	694	N/A	N/A	N/A
3/31/2022	13,978	537	1,489	2,201	N/A
12/31/2021	13,312	-544	N/A	N/A	N/A
9/30/2021	12,472	-379	1,089	1,510	N/A
6/30/2021	11,431	-1,633	N/A	N/A	N/A
3/31/2021	10,134	-1,935	851	1,205	N/A
12/31/2020	9,858	-1,349	N/A	N/A	N/A
9/30/2020	9,897	-1,284	751	1,271	N/A
6/30/2020	10,202	-1,284	N/A	N/A	N/A
3/31/2020	10,956	-1,067	223	1,301	N/A
12/31/2019	10,832	-718	N/A	N/A	N/A
9/30/2019	10,541	-552	N/A	N/A	N/A
6/30/2019	10,210	-394	N/A	N/A	N/A
3/31/2019	9,787	-248	-903	985	N/A
12/31/2018	9,430	-135	N/A	N/A	N/A
9/30/2018	9,004	-41	N/A	N/A	N/A
6/30/2018	8,661	124	N/A	N/A	N/A
3/31/2018	8,307	205	N/A	978	N/A
12/31/2017	7,909	257	N/A	N/A	N/A
9/30/2017	7,608	278	N/A	N/A	N/A
6/30/2017	7,237	219	N/A	N/A	N/A
3/31/2017	7,001	230	N/A	913	N/A
12/31/2016	6,705	208	N/A	N/A	N/A
9/30/2016	6,392	133	N/A	N/A	N/A
6/30/2016	6,081	67	N/A	N/A	N/A
3/31/2016	5,842	-178	N/A	732	N/A
12/31/2015	5,611	-33	N/A	N/A	N/A
9/30/2015	5,494	9	N/A	763	N/A
6/30/2015	5,323	9	N/A	N/A	N/A
3/31/2015	5,194	8	N/A	597	N/A
3/31/2014	4,513	-356	N/A	514	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: HCG 'nin tahmini kazanç büyümesi (yıllık 59.7% ) tasarruf oranının ( 6.7% ) üzerindedir.

Kazançlar ve Piyasa: HCG şirketinin kazançlarının (yıllık 59.7% ) Indian pazarından (yıllık 17.7% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: HCG şirketinin kazançlarının önümüzdeki 3 yıl içerisinde önemli ölçüde artması bekleniyor.

Gelir ve Pazar: HCG şirketinin gelirinin (yıllık 14.5% ) Indian pazarından (yıllık 10.6% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: HCG şirketinin gelirinin (yıllık 14.5% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: HCG 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 14.9 %).

Büyüyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/03/19 01:49
Gün Sonu Hisse Fiyatı	2025/03/19 00:00
Kazançlar	2024/12/31
Yıllık Kazançlar	2024/03/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

HealthCare Global Enterprises Limited 22 Bu analistlerden 6, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Candice Pereira	Anand Rathi Shares and Stock Brokers Limited
Kripashankar Maurya	Choice Equity Broking Private Limited
Deepika Murarka	Choice Equity Broking Private Limited

HealthCare Global Enterprises Gelecekteki Büyüme

Future kriter kontrolleri 4/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Consensus EPS estimates fall by 31%

Price target increased by 9.0% to ₹473

HealthCare Global Enterprises Limited Just Missed Earnings - But Analysts Have Updated Their Models

Consensus EPS estimates fall by 16%, revenue upgraded

HealthCare Global Enterprises Limited Just Missed EPS By 79%: Here's What Analysts Think Will Happen Next

Consensus EPS estimates fall by 16%

Recent updates

Now 21% undervalued after recent price drop

Insufficient new directors

KKR Asian Fund IV SCSp managed by KKR & Co. Inc. (NYSE:KKR) and KIA EBT II Scheme 1 agreed to acquire 54% stake in HealthCare Global Enterprises Limited (NSEI:HCG) from Aceso Company Pte Ltd for INR 34.3 billion.

KKR Asian Fund IV SCSp managed by KKR & Co. Inc. (NYSE:KKR) and KIA EBT II Scheme 1 agreed to acquire 54% stake in HealthCare Global Enterprises Limited (NSEI:HCG) from Aceso Company Pte Ltd for INR 34.3 billion.

Consensus EPS estimates fall by 31%

Third quarter 2025 earnings: EPS and revenues miss analyst expectations

KKR Reportedly Set to Buy Cancer Chain HCG

Meghraj Arvindrao Gore, Whole-Time Director Completes Term as a Director of Healthcare Global Enterprises Limited on the Board on February 09, 2025

HealthCare Global Enterprises Limited to Report Q3, 2025 Results on Feb 13, 2025

Pinning Down HealthCare Global Enterprises Limited's (NSE:HCG) P/S Is Difficult Right Now

KKR Reportedly Close to Buying HCG

Price target increased by 9.0% to ₹473

HealthCare Global Enterprises Limited Just Missed Earnings - But Analysts Have Updated Their Models

Second quarter 2025 earnings: EPS misses analyst expectations

HealthCare Global Enterprises Limited Announces the Resignation of Mr. Jeyandran Venugopal as from the Board and Member of Nomination and Remuneration Committee and Corporate Social Responsibility Committee of the Board

HealthCare Global Enterprises Limited to Report Q2, 2025 Results on Nov 09, 2024

HealthCare Global Enterprises Limited (NSEI:HCG) completed the acquisition of 51% stake in Vizag Hospital and Cancer Research Centre Private Limited.

We Take A Look At Why HealthCare Global Enterprises Limited's (NSE:HCG) CEO Compensation Is Well Earned

HealthCare Global Enterprises Limited, Annual General Meeting, Sep 25, 2024

Consensus EPS estimates fall by 16%, revenue upgraded

First quarter 2025 earnings released: EPS: ₹0.87 (vs ₹0.55 in 1Q 2024)

HealthCare Global Enterprises Limited to Report Q1, 2025 Results on Aug 08, 2024

HealthCare Global Enterprises Limited (NSEI:HCG) entered into share purchase agreement to acquire 51% stake in Vizag Hospital and Cancer Research Centre Private Limited for INR 2.1 billion.

HealthCare Global Enterprises Limited to Report Q4, 2024 Results on May 29, 2024

Temasek May Bid for CVC's 60% Stake in Healthcare Global

EQT, TPG and KKR Reportedly Eye Majority Stake in HCG

New major risk - Financial position

HealthCare Global Enterprises Limited Just Missed EPS By 79%: Here's What Analysts Think Will Happen Next

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

HealthCare Global Enterprises Limited to Report Q3, 2024 Results on Feb 08, 2024

Consensus EPS estimates fall by 16%

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

HealthCare Global Enterprises Limited to Report Q2, 2024 Results on Nov 09, 2023

HealthCare Global Enterprises Limited (NSEI:HCG) completed the acquisition of Radiation Business from Amrish Oncology Services Private Limited.

HealthCare Global Enterprises Limited (NSEI:HCG) completed the acquisition of Oncology Business from SRJ Health Care Private Limited.

CVC Capital Mulls Selling Stake in HealthCare Global Enterprises

We Think Shareholders Will Probably Be Generous With HealthCare Global Enterprises Limited's (NSE:HCG) CEO Compensation

A Look At The Fair Value Of HealthCare Global Enterprises Limited (NSE:HCG)

HealthCare Global Enterprises Limited, Annual General Meeting, Sep 20, 2023

HealthCare Global Enterprises Limited (NSEI:HCG) completed the acquisition of Nagpur Cancer Hospital & Research Institute Private Limited from Ajay Mehta, Suchitra Mehta and other shareholders.

HealthCare Global Enterprises Limited Announces CFO Changes

Consensus EPS estimates increase by 12%

New major risk - Financial position

HealthCare Global Enterprises Limited (NSEI:HCG) executed business transfer agreement to acquire Radiation Business from Amrish Oncology Services Private Limited for INR 160 million.

First quarter 2024 earnings: EPS misses analyst expectations

HealthCare Global Enterprises Limited to Report Q1, 2024 Results on Aug 10, 2023

HealthCare Global Enterprises Limited (NSEI:HCG) entered into a share purchase agreement to acquire Nagpur Cancer Hospital & Research Institute Private Limited from Ajay Mehta, Suchitra Mehta and other shareholders for approximately INR 140 million.

Executive Chairman recently sold ₹1.1b worth of stock

Full year 2023 earnings: EPS misses analyst expectations

Consensus EPS estimates fall by 11%

HealthCare Global Enterprises Limited's (NSE:HCG) Business Is Yet to Catch Up With Its Share Price

HealthCare Global Enterprises Limited to Report Q4, 2023 Results on May 25, 2023

Insider recently sold ₹794k worth of stock

Insider recently sold ₹1.7m worth of stock

Insider recently sold ₹2.9m worth of stock

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

HealthCare Global Enterprises Limited to Report Q3, 2023 Results on Feb 09, 2023

Insider recently sold ₹846k worth of stock

Insider recently sold ₹332k worth of stock

High number of new and inexperienced directors

Second quarter 2023 earnings released: EPS: ₹0.53 (vs ₹8.22 in 2Q 2022)

HealthCare Global Enterprises Limited to Report Q2, 2023 Results on Nov 10, 2022

HealthCare Global Enterprises Limited, Annual General Meeting, Sep 29, 2022

HealthCare Global Enterprises Limited, Annual General Meeting, Sep 29, 2022

Price target decreased to ₹350

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

HealthCare Global Enterprises Limited to Report Q1, 2023 Results on Aug 10, 2022

Executive Chairman recently sold ₹500m worth of stock

HealthCare Global Enterprises Limited (BSE:539787) agreed to acquire Radiation therapy centre of Radiant Hospital Services Private Limited from Radiant Hospitality Services Private Limited for INR 160 million.